National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No.2)
Instrument number PB 17 of 2012
National Health Act 1953
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the
Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated 27 March 2012
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
Part 1 Preliminary
1 Name of Determination
(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No.2).
(2) This Determination may also be cited as PB 17 of 2012.
2 Commencement
This Determination commences on 1 April 2012.
3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1 Amendments
(Section 3)
[1] Schedule 1, after item dealing with Anakinra
Omit
Anastrozole
[2] Schedule 1, after item dealing with Atomoxetine
Omit
Atorvastatin
[3] Schedule 1, after item dealing with Lenograstim
Omit
Letrozole
[4] Schedule 1, after item dealing with Mupirocin
Omit
Mycophenolic acid
[5] Schedule 1, after item dealing with Ofloxacin
Omit
Olanzapine
[6] Schedule 1, after item dealing with Pyrimethamine
Omit
Quetiapine
[7] Schedule 1, after item dealing with Rifampicin
Insert
Rilpivirine
[8] Schedule 1, after item dealing with Rosiglitazone
Omit
Rosuvastatin
[9] Schedule 1, after item dealing with Sunitinib
Insert
Tadalafil
[10] Schedule 1, after item dealing with Varenicline
Omit
Venlafaxine
[11] Schedule 2, after item dealing with Ampicillin
Insert
Anastrozole
[12] Schedule 2, after item dealing with Atenolol
Insert
Atorvastatin
[13] Schedule 2, after item dealing with Lercanidipine
Insert
Letrozole
[14] Schedule 2, after item dealing with Morphine
Insert
Mycophenolic acid
[15] Schedule 2, after item dealing with Oestradiol
Insert
Olanzapine
[16] Schedule 2, after item dealing with Prochlorperazine
Insert
Quetiapine
[17] Schedule 2, after item dealing with Risperidone
Insert
Rosuvastatin
[18] Schedule 2, after item dealing with Vancomycin
Insert
Venlafaxine
Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.
